Adjunct to a reduced-calorie diet & increased physical activity for wt management in adult patients w/ an initial BMI of ≥30 kg/m2 (obese), or ≥27 kg/m2 to <30 kg/m2 (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea. Adjunct to a healthy nutrition & increased physical activity for wt management in adolescents ≥12 yr w/ obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points), & body wt >60 kg.
Do not administer by IV or IM. Risk of developing acute pancreatitis. Higher rate of cholelithiasis & cholecystitis. Reports of thyroid adverse events (eg, goitre), particularly in patients w/ pre-existing thyroid disease. Increase in heart rate. Potential risk of dehydration. Increased risk of hypoglycaemia in patients w/ type 2 DM receiving concomitant insulin &/or sulfonylurea. Reports of episodes of clinically significant hypoglycaemia in adolescents ≥12 yr. Not a substitute for insulin in patients w/ DM. Not recommended in patients w/ CHF NYHA class IV; obesity secondary to endocrinological or eating disorders or to treatment w/ medicinal products that may cause wt gain; inflammatory bowel disease & diabetic gastroparesis; severe renal impairment (CrCl <30 mL/min) including ESRD; severe hepatic impairment; elderly ≥75 yr; patients treated w/ other products for wt management. Use w/ caution in patients w/ mild or moderate hepatic impairment. Do not use w/ other GLP-1 receptor agonist in patients w/ type 2 DM. May impair ability to drive & use machines. Do not use during pregnancy & breast-feeding. Safety & efficacy in childn <12 yr has not been established.
Sign Out
 6 mg_mL579b0d6a-807a-44f8-942f-a93f00a4a998.GIF)
